New perspectives in occult hepatitis C virus infection

Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 18; no. 23; pp. 2887 - 2894
Main Author Vicente Carreno Javier Bartolome Inmaculada Castillo Juan Antonio Quiroga
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 21.06.2012
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v18.i23.2887

Cover

Abstract Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.
AbstractList Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.
Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.
Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.
Author Vicente Carreno Javier Bartolome Inmaculada Castillo Juan Antonio Quiroga
AuthorAffiliation Foundation for the Study of Viral Hepa-titis, C/Guzman el Bueno 72, 28015 Madrid, Spain
Author_xml – sequence: 1
  fullname: Vicente Carreno Javier Bartolome Inmaculada Castillo Juan Antonio Quiroga
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22736911$$D View this record in MEDLINE/PubMed
BookMark eNp9kTFv2zAQhYkiReMk3TMF6tZFLu8oieRSoDDaJEDQLu1MUPTJZiCTiig56L-PhDhG0yHTDfe99w73zthJiIEYuwS-FLJQXx7vN8s9qKVHsUSl5Du2QASdoyr4CVsA5zLXAuUpO0vpnnMUosQP7BRRikoDLFj1kx6zjvrUkRv8nlLmQxadG9sh21JnBz_4lK2yve_HedfMWAwX7H1j20QfD_Oc_fnx_ffqJr_7dX27-naXuyloyAVQU9VNralEQisbgFprK20zX2CtVriWuK5RFrVSAK5CkLTWKEoNBRTinH199u3GekdrR2HobWu63u9s_9dE683rTfBbs4l7I4TiAsrJ4PPBoI8PI6XB7Hxy1LY2UByTAY5YlprzGb36N-sY8vKsCeDPgOtjSj01RwS4mfswUx9m6sNMfZi5j0lS_SdxfrDzB6drffuW8NNBuI1h8-DD5hhWYMk1lJV4AhTmnG0
CitedBy_id crossref_primary_10_1007_s00005_015_0364_8
crossref_primary_10_6002_ect_2017_0332
crossref_primary_10_1007_s00705_018_4066_5
crossref_primary_10_1111_trf_13127
crossref_primary_10_1111_liv_12320
crossref_primary_10_1007_s00005_013_0257_7
crossref_primary_10_1111_jvh_12526
crossref_primary_10_5812_jjm_8_4_2015_17157
crossref_primary_10_1007_s11356_017_0897_y
crossref_primary_10_1016_j_jiph_2022_11_008
crossref_primary_10_5812_ircmj_34181
crossref_primary_10_1007_s10096_013_1857_1
crossref_primary_10_1002_jmv_25279
crossref_primary_10_5812_hepatmon_16089
crossref_primary_10_4254_wjh_v13_i2_242
crossref_primary_10_1016_j_meegid_2019_104144
crossref_primary_10_1097_CAD_0b013e32835ec39a
crossref_primary_10_1002_jmv_24467
crossref_primary_10_1111_hepr_13325
crossref_primary_10_1002_jmv_24074
crossref_primary_10_1007_s00705_018_3922_7
crossref_primary_10_1007_s00705_016_3049_7
crossref_primary_10_1177_039463201402700111
crossref_primary_10_1186_1471_2334_12_S2_S2
crossref_primary_10_1371_journal_pone_0205659
crossref_primary_10_15406_ppij_2023_11_00394
crossref_primary_10_1111_vox_12547
crossref_primary_10_1002_jmv_25808
crossref_primary_10_5812_jjm_121929
crossref_primary_10_1111_vox_12301
crossref_primary_10_1177_2058738420961202
crossref_primary_10_4254_wjh_v6_i6_419
crossref_primary_10_1007_s12288_018_0968_3
crossref_primary_10_1155_2015_579147
crossref_primary_10_1002_jmv_25769
crossref_primary_10_18821_0507_4088_2019_64_1_30_35
crossref_primary_10_1002_hep_27626
crossref_primary_10_29252_JoMMID_8_1_1
crossref_primary_10_1007_s10238_022_00791_7
crossref_primary_10_1007_s00705_016_2862_3
crossref_primary_10_3748_wjg_v21_i38_10790
crossref_primary_10_2174_1568026619666190510094228
crossref_primary_10_5812_hepatmon_16665
crossref_primary_10_1016_j_ajg_2018_09_001
crossref_primary_10_5812_hepatmon_11290
crossref_primary_10_1159_000455854
crossref_primary_10_1007_s00431_014_2286_6
crossref_primary_10_1080_00365521_2020_1790649
crossref_primary_10_21320_2500_2139_2023_16_1_46_53
crossref_primary_10_1016_j_ajg_2021_03_001
crossref_primary_10_1158_1055_9965_EPI_13_0397
crossref_primary_10_3748_wjg_v24_i20_2191
crossref_primary_10_4292_wjgpt_v7_i1_33
crossref_primary_10_1007_s13337_024_00881_y
crossref_primary_10_34172_mejdd_2022_275
crossref_primary_10_5662_wjm_v12_i3_179
crossref_primary_10_7314_APJCP_2012_13_12_5917
crossref_primary_10_4254_wjh_v9_i33_1239
ContentType Journal Article
Copyright 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
Copyright_xml – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v18.i23.2887
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate New perspectives in occult hepatitis C virus infection
EISSN 2219-2840
EndPage 2894
ExternalDocumentID PMC3380315
22736911
10_3748_wjg_v18_i23_2887
42509156
Genre Research Support, Non-U.S. Gov't
Editorial
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c352t-31ef6bfb9e52e2a7f11b99a7af2273aa982d72db274b8811c6217ed9235914143
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 13:34:38 EDT 2025
Fri Jul 11 00:06:00 EDT 2025
Mon Jul 21 05:52:26 EDT 2025
Tue Jul 01 03:21:55 EDT 2025
Thu Apr 24 23:05:30 EDT 2025
Wed Feb 14 10:46:24 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 23
Keywords Peripheral blood mononuclear cells
Hepatitis C virus RNA
Occult hepatitis C virus
Liver
T-cell response
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c352t-31ef6bfb9e52e2a7f11b99a7af2273aa982d72db274b8811c6217ed9235914143
Notes Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.
14-1219/R
Occult hepatitis C virus; Hepatitis C virusRNA; Liver; Peripheral blood mononuclear cells; T-cellresponse
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
Author contributions: Carreño V, Bartolomé J, Castillo I and Quiroga JA equally contributed to generating the ideas for this review and writing this manuscript.
Correspondence to: Vicente Carreño, MD, PhD, Foundation for the Study of Viral Hepatitis, C/Guzmán el Bueno 72, 28015 Madrid, Spain. fehvhpa@fehv.org
Telephone: +34-91-5446013 Fax: +34-91-5449228
OpenAccessLink https://www.wjgnet.com/1007-9327/full/v18/i23/2887.htm
PMID 22736911
PQID 1022559005
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3380315
proquest_miscellaneous_1022559005
pubmed_primary_22736911
crossref_primary_10_3748_wjg_v18_i23_2887
crossref_citationtrail_10_3748_wjg_v18_i23_2887
chongqing_primary_42509156
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-06-21
PublicationDateYYYYMMDD 2012-06-21
PublicationDate_xml – month: 06
  year: 2012
  text: 2012-06-21
  day: 21
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2012
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 16323211 - Hepatology. 2006 Jan;43(1):91-9
11055514 - Curr Opin Hematol. 2000 Nov;7(6):397-401
16611276 - Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9
10365827 - J Hepatol. 1999 May;30(5):956-61
16537674 - J Clin Pathol. 2006 May;59(5):526-9
21699630 - J Viral Hepat. 2012 Feb;19(2):103-11
17181568 - Eur J Clin Invest. 2007 Jan;37(1):54-64
18712814 - J Med Virol. 2008 Oct;80(10):1720-2
18505381 - J Infect Dis. 2008 Jul 15;198(2):203-12
15140984 - J Virol. 2004 Jun;78(11):5867-74
15736006 - Clin Infect Dis. 2005 Mar 15;40(6):e49-54
19523175 - Aliment Pharmacol Ther. 2009 Sep 1;30(5):477-86
20960374 - Semin Liver Dis. 2010 Nov;30(4):333-47
20648609 - J Med Virol. 2010 Sep;82(9):1554-9
14518724 - J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204
9620345 - Hepatology. 1998 Jun;27(6):1700-2
15619235 - Hepatology. 2005 Jan;41(1):106-14
18647233 - J Viral Hepat. 2009 Jan;16(1):10-20
11583749 - Lancet. 2001 Sep 22;358(9286):958-65
17021056 - J Clin Microbiol. 2006 Dec;44(12):4559-60
20070513 - Liver Int. 2010 Apr;30(4):502-11
15964345 - Transplant Proc. 2005 Jun;37(5):2083-5
21184846 - Infect Genet Evol. 2011 Mar;11(2):442-5
7597443 - Semin Liver Dis. 1995 Feb;15(1):41-63
9403936 - Res Virol. 1997 Sep-Oct;148(5):367-73
10859368 - J Gen Virol. 2000 Jul;81(Pt 7):1631-48
22093326 - Liver Int. 2011 Nov;31(10):1519-24
15319859 - J Infect Dis. 2004 Sep 15;190(6):1093-7
17475654 - J Virol. 2007 Jul;81(14):7710-5
15838801 - J Infect Dis. 2005 May 15;191(10):1730-3
12107020 - Lancet Oncol. 2002 Jun;3(6):333-40
17071928 - J Virol. 2006 Nov;80(22):10972-9
21205133 - Liver Int. 2011 Jan;31 Suppl 1:18-22
15122521 - J Infect Dis. 2004 May 15;189(10):1846-55
15664228 - Lancet. 2005 Jan 22-28;365(9456):327-9
15831916 - Gut. 2005 May;54(5):682-5
18265423 - Rev Med Virol. 2008 May-Jun;18(3):139-57
16474148 - J Virol. 2006 Mar;80(5):2418-28
16741882 - J Infect Dis. 2006 Jul 1;194(1):53-60
15589744 - Transpl Immunol. 2004 Dec;13(4):305-11
17051492 - Clin Infect Dis. 2006 Nov 15;43(10):1277-83
19215578 - J Viral Hepat. 2009 Aug;16(8):547-56
14635013 - J Med Virol. 2004 Jan;72(1):66-74
10802716 - Nat Med. 2000 May;6(5):578-82
16847959 - J Med Virol. 2006 Sep;78(9):1190-7
9807989 - Lancet. 1998 Oct 31;352(9138):1426-32
21503911 - J Med Virol. 2011 Jun;83(6):989-95
14702147 - J Infect Dis. 2004 Jan 1;189(1):7-14
19956542 - PLoS One. 2009;4(12):e8128
19475603 - J Med Virol. 2009 Jul;81(7):1198-203
20380524 - Immunol Invest. 2010 Jan;39(3):284-91
15168768 - Intern Med. 2004 Apr;43(4):279-82
16406797 - J Clin Virol. 2006 Apr;35(4):368-72
16107964 - J Infect Dis. 2005 Sep 15;192(6):1088-92
15191008 - Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5
19330875 - Hepatology. 2009 Apr;49(4):1335-74
17650287 - J Viral Hepat. 2007 Aug;14(8):537-48
19070391 - J Hepatol. 2009 Feb;50(2):256-63
16122679 - Lancet Infect Dis. 2005 Sep;5(9):558-67
8058787 - Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43
20345213 - Crit Rev Microbiol. 2010 May;36(2):91-133
18684893 - J Am Soc Nephrol. 2008 Dec;19(12):2288-92
10622555 - J Hepatol. 1999;31 Suppl 1:17-24
16569433 - J Infect. 2007 Feb;54(2):173-9
17212642 - J Viral Hepat. 2007 Jan;14(1):36-40
21040725 - Gastroenterology. 2011 Feb;140(2):676-685.e1
References_xml – reference: 16847959 - J Med Virol. 2006 Sep;78(9):1190-7
– reference: 20648609 - J Med Virol. 2010 Sep;82(9):1554-9
– reference: 15191008 - Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5
– reference: 17181568 - Eur J Clin Invest. 2007 Jan;37(1):54-64
– reference: 19330875 - Hepatology. 2009 Apr;49(4):1335-74
– reference: 17021056 - J Clin Microbiol. 2006 Dec;44(12):4559-60
– reference: 18505381 - J Infect Dis. 2008 Jul 15;198(2):203-12
– reference: 17650287 - J Viral Hepat. 2007 Aug;14(8):537-48
– reference: 20345213 - Crit Rev Microbiol. 2010 May;36(2):91-133
– reference: 17051492 - Clin Infect Dis. 2006 Nov 15;43(10):1277-83
– reference: 15664228 - Lancet. 2005 Jan 22-28;365(9456):327-9
– reference: 16537674 - J Clin Pathol. 2006 May;59(5):526-9
– reference: 17071928 - J Virol. 2006 Nov;80(22):10972-9
– reference: 11055514 - Curr Opin Hematol. 2000 Nov;7(6):397-401
– reference: 21040725 - Gastroenterology. 2011 Feb;140(2):676-685.e1
– reference: 15619235 - Hepatology. 2005 Jan;41(1):106-14
– reference: 15964345 - Transplant Proc. 2005 Jun;37(5):2083-5
– reference: 10365827 - J Hepatol. 1999 May;30(5):956-61
– reference: 10622555 - J Hepatol. 1999;31 Suppl 1:17-24
– reference: 8058787 - Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43
– reference: 12107020 - Lancet Oncol. 2002 Jun;3(6):333-40
– reference: 19070391 - J Hepatol. 2009 Feb;50(2):256-63
– reference: 15140984 - J Virol. 2004 Jun;78(11):5867-74
– reference: 16611276 - Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9
– reference: 14518724 - J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):198-204
– reference: 16107964 - J Infect Dis. 2005 Sep 15;192(6):1088-92
– reference: 21699630 - J Viral Hepat. 2012 Feb;19(2):103-11
– reference: 21184846 - Infect Genet Evol. 2011 Mar;11(2):442-5
– reference: 16474148 - J Virol. 2006 Mar;80(5):2418-28
– reference: 15831916 - Gut. 2005 May;54(5):682-5
– reference: 14635013 - J Med Virol. 2004 Jan;72(1):66-74
– reference: 9807989 - Lancet. 1998 Oct 31;352(9138):1426-32
– reference: 16323211 - Hepatology. 2006 Jan;43(1):91-9
– reference: 19215578 - J Viral Hepat. 2009 Aug;16(8):547-56
– reference: 21503911 - J Med Virol. 2011 Jun;83(6):989-95
– reference: 14702147 - J Infect Dis. 2004 Jan 1;189(1):7-14
– reference: 9620345 - Hepatology. 1998 Jun;27(6):1700-2
– reference: 20960374 - Semin Liver Dis. 2010 Nov;30(4):333-47
– reference: 16122679 - Lancet Infect Dis. 2005 Sep;5(9):558-67
– reference: 17475654 - J Virol. 2007 Jul;81(14):7710-5
– reference: 15838801 - J Infect Dis. 2005 May 15;191(10):1730-3
– reference: 18265423 - Rev Med Virol. 2008 May-Jun;18(3):139-57
– reference: 15168768 - Intern Med. 2004 Apr;43(4):279-82
– reference: 16406797 - J Clin Virol. 2006 Apr;35(4):368-72
– reference: 19523175 - Aliment Pharmacol Ther. 2009 Sep 1;30(5):477-86
– reference: 21205133 - Liver Int. 2011 Jan;31 Suppl 1:18-22
– reference: 22093326 - Liver Int. 2011 Nov;31(10):1519-24
– reference: 15736006 - Clin Infect Dis. 2005 Mar 15;40(6):e49-54
– reference: 10859368 - J Gen Virol. 2000 Jul;81(Pt 7):1631-48
– reference: 18684893 - J Am Soc Nephrol. 2008 Dec;19(12):2288-92
– reference: 18712814 - J Med Virol. 2008 Oct;80(10):1720-2
– reference: 15319859 - J Infect Dis. 2004 Sep 15;190(6):1093-7
– reference: 17212642 - J Viral Hepat. 2007 Jan;14(1):36-40
– reference: 20070513 - Liver Int. 2010 Apr;30(4):502-11
– reference: 15122521 - J Infect Dis. 2004 May 15;189(10):1846-55
– reference: 7597443 - Semin Liver Dis. 1995 Feb;15(1):41-63
– reference: 16741882 - J Infect Dis. 2006 Jul 1;194(1):53-60
– reference: 19475603 - J Med Virol. 2009 Jul;81(7):1198-203
– reference: 11583749 - Lancet. 2001 Sep 22;358(9286):958-65
– reference: 20380524 - Immunol Invest. 2010 Jan;39(3):284-91
– reference: 19956542 - PLoS One. 2009;4(12):e8128
– reference: 15589744 - Transpl Immunol. 2004 Dec;13(4):305-11
– reference: 9403936 - Res Virol. 1997 Sep-Oct;148(5):367-73
– reference: 16569433 - J Infect. 2007 Feb;54(2):173-9
– reference: 10802716 - Nat Med. 2000 May;6(5):578-82
– reference: 18647233 - J Viral Hepat. 2009 Jan;16(1):10-20
SSID ssj0023352
Score 2.2846944
Snippet Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of...
Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of...
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2887
SubjectTerms Antiviral Agents - therapeutic use
Asymptomatic Infections
Hepacivirus - genetics
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - immunology
Humans
Leukocytes, Mononuclear - chemistry
Liver - chemistry
RNA, Viral - analysis
Serologic Tests
T细胞反应
丙型肝炎病毒
外周血单个核细胞
抗原特异性
抗病毒治疗
病毒感染
肝脏疾病
隐匿性
Title New perspectives in occult hepatitis C virus infection
URI http://lib.cqvip.com/qk/84123X/201223/42509156.html
https://www.ncbi.nlm.nih.gov/pubmed/22736911
https://www.proquest.com/docview/1022559005
https://pubmed.ncbi.nlm.nih.gov/PMC3380315
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgXLigTXxlAxQkLmhK1ziJ7RxZBZomwWmD3SzbcboglIw23aT99bxnJ2laNolxiarUfXL8S59_7_l9EPLB-TYKbiJh0iRKmbGRorSMppYLBe9zzDjmO3_9xk7O09OL7GLd7c1ll7R6Ym7vzCv5H1ThHuCKWbIPQHYQCjfgM-ALV0AYrv-EMQYnXq2zJV1oa2OwmAYQQAyVbqvl4ezwulqs1mFX9ZiP-liaUfmIuVq2iwYLdS58dSZ0Gfw4HTpwzTC0F0_Xj2PnZP1eYXinHTsPMAqDRT4judN36KkECsfvVoirPhu4V2_C747behdr2MBi3fycT65jMaloMumHbpa43tp6hoBAMEVQhgQJYLYLCRIkSnhMnlDO3fm7c8N0ljQmirlj7G72_vwZJRxtzwFrZlw29fw3MIFN7vGXQbEdFzsiGme75FlnIYSfPNx75JGtnxMGUIdjqMOqDj3U4QB1OAsd1OEA9Qty_uXz2ewk6lpeRAYeqYUd0ZZMlzq3GbVU8TKOdZ4rrkoKPFOpXNCC00JTnmoh4tgwMCltASw9y-MUuO9LslM3tX1NQpExU5gysUjhLBWawrgkzXmip3aamYDsDwsjr3xpEwkaHAhkxgJy1K-UNF2xeOxZ8kveh1RAPg6_6KXdP_Z9v_gStBkeUanaNqulRP9Dho1ss4C88mAM0nAFGOzNAeEbMA0DsFL65jd1dekqpieJwG4m-w-Y4wF5uv7DvCE77WJl3wL_bPU79y7-AbKZhlM
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+perspectives+in+occult+hepatitis+C+virus+infection&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Carre%C3%B1o%2C+Vicente&rft.date=2012-06-21&rft.issn=1007-9327&rft.volume=18&rft.issue=23&rft.spage=2887&rft_id=info:doi/10.3748%2Fwjg.v18.i23.2887&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v18_i23_2887
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg